Drug intelligence / Profile preview

IBI101 + sintilimab

Development stage: Unknown
Lead developer: Innovent Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IBI101 + sintilimab is a combination of two monoclonal antibodies intended for cancer immunotherapy. IBI101 is an anti-OX40 antibody that stimulates the OX40 pathway, activating effector T cells and enhancing the anti-tumor immune response. Sintilimab (marketed as Tyvyt) is an anti-PD-1 antibody that inhibits the PD-1 immune checkpoint to restore and enhance T cell-mediated antitumor activity. The combination is under investigation for the treatment of advanced solid tumors, and its therapeutic approach leverages the synergistic effects of immune checkpoint inhibition and T cell activation[3].

Other names: IBI101 + Tyvyt

Targets

CD28 (Cluster of Differentiation 28)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on IBI101 + sintilimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBI101 + sintilimab.

Explore the full profile